19 agosto 2014
In its second dossier, the drug manufacturer deviated from the appropriate comparator therapy and again provided no relevant data for the assessment of the added benefit of perampanel, experts report.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/15BfQQUrwIM/140819125950.htm
